PROGENICS PHARMACEUTICALS INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

Item 7.01. Regulation FD Disclosure.

On March 18, 2020, Progenics Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the results from the Phase 3 CONDOR trial evaluating the diagnostic performance and clinical impact of PyLTM (18F-DCFPyL) in men with biochemical recurrence of prostate cancer will be presented in an oral session at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program. A copy of the foregoing press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated in this Item 7.01 by reference.

The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01       Financial Statements and Exhibits



(d)     Exhibits.



Exhibit
  No.       Description

 99.1         Press Release announcing presentation of results from the Phase 3
            CONDOR trial at the American Society of Clinical Oncology 2020 Virtual
            Scientific Program, dated May 18, 2020.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses